Hormonal
GLP-1 analogues (liraglutide, semaglutide, tirzepatide, efpeglenatide) combined with lifestyle interventions produce significant weight loss (5-15%) and reduce cardiometabolic risk in adults with obesity.
GLP-1 medications like semaglutide and liraglutide are effective tools for weight loss when combined with diet and exercise. They work by slowing digestion and reducing appetite. While gastrointestinal side effects like nausea are common, they often subside. These drugs are approved for adults with high BMI or obesity-related comorbidities.
O uso de análogos do GLP-1 combinado com tratamento não farmacológico mostra-se eficaz para o tratamento da obesidade, pois retardam o esvaziamento gástrico e diminuem o apetite, contribuindo para redução de peso corporal (TUTTLE, 2021).
Why this rating
Based on a literature review citing multiple randomized controlled trials and meta-analyses.
Source
Tratamento da obesidade com análogos de GLP-1: uma revisão de literatura
Gabriel Dantas Ardais et al. · Revista Interdisciplinar de Saúde e Educação · 2023
DOI 10.56344/2675-4827.v4n3a2023.30
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →